Virginia Opioid Addiction ECHO* Clinic Feb 15.pdf• However after induction both bupe/nal and xr...
Transcript of Virginia Opioid Addiction ECHO* Clinic Feb 15.pdf• However after induction both bupe/nal and xr...
![Page 1: Virginia Opioid Addiction ECHO* Clinic Feb 15.pdf• However after induction both bupe/nal and xr naltrexone are similar • Patient selection and ancillary supports to keep individuals](https://reader035.fdocuments.in/reader035/viewer/2022070801/5f02a4d37e708231d4054aa9/html5/thumbnails/1.jpg)
Virginia Opioid Addiction ECHO*ClinicFebruary 15, 2019
*ECHO: Extension of Community Healthcare Outcomes
![Page 2: Virginia Opioid Addiction ECHO* Clinic Feb 15.pdf• However after induction both bupe/nal and xr naltrexone are similar • Patient selection and ancillary supports to keep individuals](https://reader035.fdocuments.in/reader035/viewer/2022070801/5f02a4d37e708231d4054aa9/html5/thumbnails/2.jpg)
Rename
Helpful Reminders
• Rename your Zoom screen, with your name and organization
![Page 3: Virginia Opioid Addiction ECHO* Clinic Feb 15.pdf• However after induction both bupe/nal and xr naltrexone are similar • Patient selection and ancillary supports to keep individuals](https://reader035.fdocuments.in/reader035/viewer/2022070801/5f02a4d37e708231d4054aa9/html5/thumbnails/3.jpg)
Unmute
Helpful Reminders
• You are all on muteplease unmute to talk
• If joining by telephone audio only, *6 to mute and unmute
![Page 4: Virginia Opioid Addiction ECHO* Clinic Feb 15.pdf• However after induction both bupe/nal and xr naltrexone are similar • Patient selection and ancillary supports to keep individuals](https://reader035.fdocuments.in/reader035/viewer/2022070801/5f02a4d37e708231d4054aa9/html5/thumbnails/4.jpg)
Chat Box
Helpful Reminders
• Please type your full name and organization into the chat box
• Use the chat function to speak with IT or ask questions
![Page 5: Virginia Opioid Addiction ECHO* Clinic Feb 15.pdf• However after induction both bupe/nal and xr naltrexone are similar • Patient selection and ancillary supports to keep individuals](https://reader035.fdocuments.in/reader035/viewer/2022070801/5f02a4d37e708231d4054aa9/html5/thumbnails/5.jpg)
• Bi-Weekly 1.5 hour tele-ECHO Clinics
• Every tele-ECHO clinic includes a 30 minute didactic presentation followed by case
discussions
• Didactic presentations are developed and delivered by inter-professional
experts in substance use disorder
• Website Link: www.vcuhealth.org/echo
VCU Opioid Addiction ECHO Clinics
![Page 6: Virginia Opioid Addiction ECHO* Clinic Feb 15.pdf• However after induction both bupe/nal and xr naltrexone are similar • Patient selection and ancillary supports to keep individuals](https://reader035.fdocuments.in/reader035/viewer/2022070801/5f02a4d37e708231d4054aa9/html5/thumbnails/6.jpg)
VCU Team
Clinical Director Mishka Terplan, MD, MPH, FACOG, FASAM
Administrative Medical Director ECHO Hub and Principal Investigator
Vimal Mishra, MD, MMCi
Clinical Expert
Didactic Presentation
Program Manager
Practice Administrator
IT Support
Lori Keyser-Marcus, PhDCourtney Holmes, PhD
Mishka Terplan, MD
Bhakti Dave, MPH
David Collins, MHA
Vladimir Lavrentyev, MBA
Hub Introductions
![Page 7: Virginia Opioid Addiction ECHO* Clinic Feb 15.pdf• However after induction both bupe/nal and xr naltrexone are similar • Patient selection and ancillary supports to keep individuals](https://reader035.fdocuments.in/reader035/viewer/2022070801/5f02a4d37e708231d4054aa9/html5/thumbnails/7.jpg)
Introductions:
• Name• Organization
Reminder: Mute and Unmute to talk*6 for phone audio Use chat function for Introduction
Poll Question #1:
• What is your current comfort level with Naltrexone?
![Page 8: Virginia Opioid Addiction ECHO* Clinic Feb 15.pdf• However after induction both bupe/nal and xr naltrexone are similar • Patient selection and ancillary supports to keep individuals](https://reader035.fdocuments.in/reader035/viewer/2022070801/5f02a4d37e708231d4054aa9/html5/thumbnails/8.jpg)
What to Expect
I. Didactic PresentationI. NaltrexoneII. Mishka Terplan, MD
II. Case presentationsI. Case 1
I. Case summary II. Clarifying questions III. Recommendations
II. Case 2 I. Case summary II. Clarifying questionsIII. Recommendations
III. Closing and questions
Lets get started!Didactic Presentation
![Page 9: Virginia Opioid Addiction ECHO* Clinic Feb 15.pdf• However after induction both bupe/nal and xr naltrexone are similar • Patient selection and ancillary supports to keep individuals](https://reader035.fdocuments.in/reader035/viewer/2022070801/5f02a4d37e708231d4054aa9/html5/thumbnails/9.jpg)
Project ECHO Naltrexone
![Page 10: Virginia Opioid Addiction ECHO* Clinic Feb 15.pdf• However after induction both bupe/nal and xr naltrexone are similar • Patient selection and ancillary supports to keep individuals](https://reader035.fdocuments.in/reader035/viewer/2022070801/5f02a4d37e708231d4054aa9/html5/thumbnails/10.jpg)
Naltrexone
• Opioid antagonist (at mu and kappa receptors)• Can be prescribed by anyone• Does not cause dependence or euphoria• “Detox Hurdle” – precipitated withdrawal if not detoxed from opioids• Oral formulation approved 1984 (OUD) and 1995 (AUD), SQ approved
2006 (AUD) and 2010 (OUD)• Cost: 50 mg tablet=$0.74/day, 380mg Injection=$41.20/day• Hepatic Metabolism
![Page 11: Virginia Opioid Addiction ECHO* Clinic Feb 15.pdf• However after induction both bupe/nal and xr naltrexone are similar • Patient selection and ancillary supports to keep individuals](https://reader035.fdocuments.in/reader035/viewer/2022070801/5f02a4d37e708231d4054aa9/html5/thumbnails/11.jpg)
Multicenter (13 sites in Russia) Funded by Alkermes DB RPCT, 24 wks, n=250 w/ opioid dependence
XR-NTX vs placebo, all offered biweekly individual drug counseling
Increased weeks of confirmed abstinence (90% vs 35%)
Increased patients with confirmed abstinence (36% vs 23%)
Decreased craving (-10 vs +0.7)
Krupitsky E et al. Lancet. 2011.
*No Black Box LFTs Warning Label for IM formulation
![Page 12: Virginia Opioid Addiction ECHO* Clinic Feb 15.pdf• However after induction both bupe/nal and xr naltrexone are similar • Patient selection and ancillary supports to keep individuals](https://reader035.fdocuments.in/reader035/viewer/2022070801/5f02a4d37e708231d4054aa9/html5/thumbnails/12.jpg)
Oral naltrexoneDuration of action 24-48 hours FDA approved 1984
10 RCTs ~700 participants to naltrexone alone or with psychosocial therapy compared with psychosocial therapy alone or placebo No clear benefit in treatment retention or relapse at
follow up
Benefit in highly motivated patients Impaired physicians > 80% abstinence at 18 months
Cochrane Database of Systematic Reviews 2006
![Page 13: Virginia Opioid Addiction ECHO* Clinic Feb 15.pdf• However after induction both bupe/nal and xr naltrexone are similar • Patient selection and ancillary supports to keep individuals](https://reader035.fdocuments.in/reader035/viewer/2022070801/5f02a4d37e708231d4054aa9/html5/thumbnails/13.jpg)
![Page 14: Virginia Opioid Addiction ECHO* Clinic Feb 15.pdf• However after induction both bupe/nal and xr naltrexone are similar • Patient selection and ancillary supports to keep individuals](https://reader035.fdocuments.in/reader035/viewer/2022070801/5f02a4d37e708231d4054aa9/html5/thumbnails/14.jpg)
![Page 15: Virginia Opioid Addiction ECHO* Clinic Feb 15.pdf• However after induction both bupe/nal and xr naltrexone are similar • Patient selection and ancillary supports to keep individuals](https://reader035.fdocuments.in/reader035/viewer/2022070801/5f02a4d37e708231d4054aa9/html5/thumbnails/15.jpg)
![Page 16: Virginia Opioid Addiction ECHO* Clinic Feb 15.pdf• However after induction both bupe/nal and xr naltrexone are similar • Patient selection and ancillary supports to keep individuals](https://reader035.fdocuments.in/reader035/viewer/2022070801/5f02a4d37e708231d4054aa9/html5/thumbnails/16.jpg)
![Page 17: Virginia Opioid Addiction ECHO* Clinic Feb 15.pdf• However after induction both bupe/nal and xr naltrexone are similar • Patient selection and ancillary supports to keep individuals](https://reader035.fdocuments.in/reader035/viewer/2022070801/5f02a4d37e708231d4054aa9/html5/thumbnails/17.jpg)
![Page 18: Virginia Opioid Addiction ECHO* Clinic Feb 15.pdf• However after induction both bupe/nal and xr naltrexone are similar • Patient selection and ancillary supports to keep individuals](https://reader035.fdocuments.in/reader035/viewer/2022070801/5f02a4d37e708231d4054aa9/html5/thumbnails/18.jpg)
![Page 19: Virginia Opioid Addiction ECHO* Clinic Feb 15.pdf• However after induction both bupe/nal and xr naltrexone are similar • Patient selection and ancillary supports to keep individuals](https://reader035.fdocuments.in/reader035/viewer/2022070801/5f02a4d37e708231d4054aa9/html5/thumbnails/19.jpg)
![Page 20: Virginia Opioid Addiction ECHO* Clinic Feb 15.pdf• However after induction both bupe/nal and xr naltrexone are similar • Patient selection and ancillary supports to keep individuals](https://reader035.fdocuments.in/reader035/viewer/2022070801/5f02a4d37e708231d4054aa9/html5/thumbnails/20.jpg)
![Page 21: Virginia Opioid Addiction ECHO* Clinic Feb 15.pdf• However after induction both bupe/nal and xr naltrexone are similar • Patient selection and ancillary supports to keep individuals](https://reader035.fdocuments.in/reader035/viewer/2022070801/5f02a4d37e708231d4054aa9/html5/thumbnails/21.jpg)
![Page 22: Virginia Opioid Addiction ECHO* Clinic Feb 15.pdf• However after induction both bupe/nal and xr naltrexone are similar • Patient selection and ancillary supports to keep individuals](https://reader035.fdocuments.in/reader035/viewer/2022070801/5f02a4d37e708231d4054aa9/html5/thumbnails/22.jpg)
Induction Failure in naltrexone arm led to relapse in 70 of 79 (89%)
Overdose events not statistically different, however study not powered for overdose
![Page 23: Virginia Opioid Addiction ECHO* Clinic Feb 15.pdf• However after induction both bupe/nal and xr naltrexone are similar • Patient selection and ancillary supports to keep individuals](https://reader035.fdocuments.in/reader035/viewer/2022070801/5f02a4d37e708231d4054aa9/html5/thumbnails/23.jpg)
![Page 24: Virginia Opioid Addiction ECHO* Clinic Feb 15.pdf• However after induction both bupe/nal and xr naltrexone are similar • Patient selection and ancillary supports to keep individuals](https://reader035.fdocuments.in/reader035/viewer/2022070801/5f02a4d37e708231d4054aa9/html5/thumbnails/24.jpg)
Conclusions
• “Induction Hurdle” for naltrexone – and high rate of relapse among induction failures
• However after induction both bupe/nal and xr naltrexone are similar• Patient selection and ancillary supports to keep individuals engaged in
care
![Page 25: Virginia Opioid Addiction ECHO* Clinic Feb 15.pdf• However after induction both bupe/nal and xr naltrexone are similar • Patient selection and ancillary supports to keep individuals](https://reader035.fdocuments.in/reader035/viewer/2022070801/5f02a4d37e708231d4054aa9/html5/thumbnails/25.jpg)
Questions?
![Page 26: Virginia Opioid Addiction ECHO* Clinic Feb 15.pdf• However after induction both bupe/nal and xr naltrexone are similar • Patient selection and ancillary supports to keep individuals](https://reader035.fdocuments.in/reader035/viewer/2022070801/5f02a4d37e708231d4054aa9/html5/thumbnails/26.jpg)
Case Presentation #1Faisal Mohsin, MD
• 12:35pm-12:55pm [20 min]• 5 min: Presentation• 2 min: Clarifying questions- Spokes (participants) • 2 min: Clarifying questions – Hub• 2 min: Recommendations – Spokes (participants) • 2 min: Recommendations – Hub• 5 min: Summary - Hub
Reminder: Mute and Unmute to talk*6 for phone audio Use chat function for questions
![Page 27: Virginia Opioid Addiction ECHO* Clinic Feb 15.pdf• However after induction both bupe/nal and xr naltrexone are similar • Patient selection and ancillary supports to keep individuals](https://reader035.fdocuments.in/reader035/viewer/2022070801/5f02a4d37e708231d4054aa9/html5/thumbnails/27.jpg)
Case Presentation #1Faisal Mohsin, MD
![Page 28: Virginia Opioid Addiction ECHO* Clinic Feb 15.pdf• However after induction both bupe/nal and xr naltrexone are similar • Patient selection and ancillary supports to keep individuals](https://reader035.fdocuments.in/reader035/viewer/2022070801/5f02a4d37e708231d4054aa9/html5/thumbnails/28.jpg)
Case Presentation #1Faisal Mohsin, MD
![Page 29: Virginia Opioid Addiction ECHO* Clinic Feb 15.pdf• However after induction both bupe/nal and xr naltrexone are similar • Patient selection and ancillary supports to keep individuals](https://reader035.fdocuments.in/reader035/viewer/2022070801/5f02a4d37e708231d4054aa9/html5/thumbnails/29.jpg)
Case Presentation #1Faisal Mohsin, MD
![Page 30: Virginia Opioid Addiction ECHO* Clinic Feb 15.pdf• However after induction both bupe/nal and xr naltrexone are similar • Patient selection and ancillary supports to keep individuals](https://reader035.fdocuments.in/reader035/viewer/2022070801/5f02a4d37e708231d4054aa9/html5/thumbnails/30.jpg)
Case Presentation #1Faisal Mohsin, MD
![Page 31: Virginia Opioid Addiction ECHO* Clinic Feb 15.pdf• However after induction both bupe/nal and xr naltrexone are similar • Patient selection and ancillary supports to keep individuals](https://reader035.fdocuments.in/reader035/viewer/2022070801/5f02a4d37e708231d4054aa9/html5/thumbnails/31.jpg)
Case Presentation #2Jennifer Phelps, BS, LPN• 12:55pm-1:25pm [20 min]
• 5 min: Presentation• 2 min: Clarifying questions- Spokes• 2 min: Clarifying questions – Hub• 2 min: Recommendations – Spokes• 2 min: Recommendations – Hub• 5 min: Summary - Hub
Reminder: Mute and Unmute to talk*6 for phone audio Use chat function for questions
![Page 32: Virginia Opioid Addiction ECHO* Clinic Feb 15.pdf• However after induction both bupe/nal and xr naltrexone are similar • Patient selection and ancillary supports to keep individuals](https://reader035.fdocuments.in/reader035/viewer/2022070801/5f02a4d37e708231d4054aa9/html5/thumbnails/32.jpg)
Case Presentation #2Jennifer Phelps, BS, LPN
![Page 33: Virginia Opioid Addiction ECHO* Clinic Feb 15.pdf• However after induction both bupe/nal and xr naltrexone are similar • Patient selection and ancillary supports to keep individuals](https://reader035.fdocuments.in/reader035/viewer/2022070801/5f02a4d37e708231d4054aa9/html5/thumbnails/33.jpg)
Case Presentation #2Jennifer Phelps, BS, LPN
![Page 34: Virginia Opioid Addiction ECHO* Clinic Feb 15.pdf• However after induction both bupe/nal and xr naltrexone are similar • Patient selection and ancillary supports to keep individuals](https://reader035.fdocuments.in/reader035/viewer/2022070801/5f02a4d37e708231d4054aa9/html5/thumbnails/34.jpg)
Case Presentation #2Jennifer Phelps, BS, LPN
![Page 35: Virginia Opioid Addiction ECHO* Clinic Feb 15.pdf• However after induction both bupe/nal and xr naltrexone are similar • Patient selection and ancillary supports to keep individuals](https://reader035.fdocuments.in/reader035/viewer/2022070801/5f02a4d37e708231d4054aa9/html5/thumbnails/35.jpg)
Case Presentation #2Jennifer Phelps, BS, LPN
![Page 36: Virginia Opioid Addiction ECHO* Clinic Feb 15.pdf• However after induction both bupe/nal and xr naltrexone are similar • Patient selection and ancillary supports to keep individuals](https://reader035.fdocuments.in/reader035/viewer/2022070801/5f02a4d37e708231d4054aa9/html5/thumbnails/36.jpg)
Case Studies and Feedback
• Case studies • Submit: www.vcuhealth.org/echo• Receive feedback from participants and content experts
• Opportunity to formally submit feedback• Survey: www.vcuhealth.org/echo• Overall feedback related to session content and flow?• Ideas for guest speakers?
![Page 37: Virginia Opioid Addiction ECHO* Clinic Feb 15.pdf• However after induction both bupe/nal and xr naltrexone are similar • Patient selection and ancillary supports to keep individuals](https://reader035.fdocuments.in/reader035/viewer/2022070801/5f02a4d37e708231d4054aa9/html5/thumbnails/37.jpg)
Access Your Evaluation and Claim Your CME
• www.vcuhealth.org/echo
• To claim CME credit for today's session
![Page 38: Virginia Opioid Addiction ECHO* Clinic Feb 15.pdf• However after induction both bupe/nal and xr naltrexone are similar • Patient selection and ancillary supports to keep individuals](https://reader035.fdocuments.in/reader035/viewer/2022070801/5f02a4d37e708231d4054aa9/html5/thumbnails/38.jpg)
Access Your Evaluation and Claim Your CME
![Page 39: Virginia Opioid Addiction ECHO* Clinic Feb 15.pdf• However after induction both bupe/nal and xr naltrexone are similar • Patient selection and ancillary supports to keep individuals](https://reader035.fdocuments.in/reader035/viewer/2022070801/5f02a4d37e708231d4054aa9/html5/thumbnails/39.jpg)
Access Your Evaluation and Claim Your CME
![Page 40: Virginia Opioid Addiction ECHO* Clinic Feb 15.pdf• However after induction both bupe/nal and xr naltrexone are similar • Patient selection and ancillary supports to keep individuals](https://reader035.fdocuments.in/reader035/viewer/2022070801/5f02a4d37e708231d4054aa9/html5/thumbnails/40.jpg)
Access Your Evaluation and Claim Your CME
• www.vcuhealth.org/echo
• To view previously recorded clinics and claim credit
![Page 41: Virginia Opioid Addiction ECHO* Clinic Feb 15.pdf• However after induction both bupe/nal and xr naltrexone are similar • Patient selection and ancillary supports to keep individuals](https://reader035.fdocuments.in/reader035/viewer/2022070801/5f02a4d37e708231d4054aa9/html5/thumbnails/41.jpg)
Access Your Evaluation and Claim Your CME
![Page 42: Virginia Opioid Addiction ECHO* Clinic Feb 15.pdf• However after induction both bupe/nal and xr naltrexone are similar • Patient selection and ancillary supports to keep individuals](https://reader035.fdocuments.in/reader035/viewer/2022070801/5f02a4d37e708231d4054aa9/html5/thumbnails/42.jpg)
Access Your Evaluation and Claim Your CME
![Page 43: Virginia Opioid Addiction ECHO* Clinic Feb 15.pdf• However after induction both bupe/nal and xr naltrexone are similar • Patient selection and ancillary supports to keep individuals](https://reader035.fdocuments.in/reader035/viewer/2022070801/5f02a4d37e708231d4054aa9/html5/thumbnails/43.jpg)
VCU Virginia Opioid Addiction TeleECHO Clinics
Bi-Weekly Fridays - 12-1:30 pm
Mark Your Calendar --- Upcoming Sessions
03/01 Pharmacotherapy for Co-Occuring SUD Gerard Moeller, MD
03/15 Policy with Maternal Substance Use Disorder Valerie L’Herrou, JD
Please refer and register at vcuhealth.org/echo
![Page 44: Virginia Opioid Addiction ECHO* Clinic Feb 15.pdf• However after induction both bupe/nal and xr naltrexone are similar • Patient selection and ancillary supports to keep individuals](https://reader035.fdocuments.in/reader035/viewer/2022070801/5f02a4d37e708231d4054aa9/html5/thumbnails/44.jpg)
THANK YOU!
Reminder: Mute and Unmute to talk*6 for phone audio Use chat function for questions